Petter Brandal

2.4k total citations
89 papers, 1.3k citations indexed

About

Petter Brandal is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Petter Brandal has authored 89 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Genetics, 28 papers in Pulmonary and Respiratory Medicine and 19 papers in Epidemiology. Recurrent topics in Petter Brandal's work include Glioma Diagnosis and Treatment (58 papers), Meningioma and schwannoma management (19 papers) and Cancer Genomics and Diagnostics (13 papers). Petter Brandal is often cited by papers focused on Glioma Diagnosis and Treatment (58 papers), Meningioma and schwannoma management (19 papers) and Cancer Genomics and Diagnostics (13 papers). Petter Brandal collaborates with scholars based in Norway, Germany and United States. Petter Brandal's co-authors include Sverre Heim, Bodil Bjerkehagen, Ioannis Panagopoulos, Ludmila Gorunova, Torstein R. Meling, David Scheie, Bernt Johan Due‐Tønnessen, Einar Osland Vik-Mo, Eirik Helseth and Tryggve Lundar and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Petter Brandal

84 papers receiving 1.3k citations

Peers

Countries citing papers authored by Petter Brandal

Since Specialization

Citations

This map shows the geographic impact of Petter Brandal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Petter Brandal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Petter Brandal more than expected).

Fields of papers citing papers by Petter Brandal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Petter Brandal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Petter Brandal. The network helps show where Petter Brandal may publish in the future.

Co-authorship network of co-authors of Petter Brandal

This figure shows the co-authorship network connecting the top 25 collaborators of Petter Brandal. A scholar is included among the top collaborators of Petter Brandal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Petter Brandal. Petter Brandal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Unveiling regional differences in glioblastoma patient survival with real-world data from the Norwegian brain tumor quality registry 2025 ·Journal of Neuro-Oncology ·Cassia B. Trewin-Nybråten, Paul C. Lambert, (unknown), Lasse Andreassen, Tom Børge Johannesen, Pitt Niehusmann, Leif Oltedal, Stephanie Schipmann, Anne Jarstein Skjulsvik, Ole Solheim, Tora S. Solheim, Terje Sundstrøm, Einar Osland Vik-Mo, Petter Brandal, Tor Ingebrigtsen, Erlend Skaga, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	0
2	Accurate and comprehensive evaluation of O6‐methylguanine‐DNA methyltransferase promoter methylation by nanopore sequencing 2024 ·Neuropathology and Applied Neurobiology ·Skarphéðinn Halldórsson, (unknown), (unknown), Petter Brandal, Ioannis Panagopoulos, Henning Leske, Marius Lund‐Iversen, Felix Sahm, Einar Osland Vik-Mo	4
3	Lomustine overdose in a patient with diffuse glioma: symptoms, management and outcome 2024 ·BMJ Case Reports ·(unknown), (unknown), (unknown), Petter Brandal	0
4	3D volume growth rate evaluation in the EORTC-BTG-1320 clinical trial for recurrent WHO grade 2 and 3 meningiomas 2024 ·Neuro-Oncology ·Émeline Tabouret, Julia Furtner, Thomas Graillon, Antonio Silvani, Émilie Le Rhun, Riccardo Soffietti, Giuseppe Lombardi, Juan Manuel Sepúlveda-Sánchez, Petter Brandal, Martin Bendszus, Vassilis Golfinopoulos, Thierry Gorlia, Michael Weller, Felix Sahm, Wolfgang Wick, Matthias Preusser	2
5	Diffuse glioma molecular profiling with arterial spin labeling and dynamic susceptibility contrast perfusion MRI: A comparative study 2024 ·Neuro-Oncology Advances ·(unknown), Andrés Server, Henning Leske, (unknown), Eirik Helseth, Roelant S. Eijgelaar, Elies Fuster‐García, Petter Brandal, Atle Bjørnerud, Jakub Otáhal, Jan Petr, Wibeke Nordhøy	2
6	Stable glioma incidence and increased patient survival over the past two decades in Norway: a nationwide registry-based cohort study 2024 ·Acta Oncologica ·Erlend Skaga, Cassia B. Trewin-Nybråten, Pitt Niehusmann, Tom Børge Johannesen, (unknown), Leif Oltedal, (unknown), Anne Jarstein Skjulsvik, Ole Solheim, Tora S. Solheim, Terje Sundstrøm, Einar Osland Vik-Mo, Petter Brandal, Tor Ingebrigtsen	1
7	The impact of cancer patient pathway on timing of radiotherapy and survival: a cohort study in glioblastoma patients 2024 ·Journal of Neuro-Oncology ·(unknown), (unknown), (unknown), (unknown), Ibrahimu Mdala, (unknown), Henriette Magelssen, Mette Sprauten, Tom Børge Johannesen, Henning Leske, Pitt Niehusmann, Karoline Skogen, Eirik Helseth, Kyrre E. Emblem, Einar Osland Vik-Mo, Petter Brandal	1
8	500O Trotabresib (CC-90010) combined with concomitant temozolomide (TMZ) plus radiotherapy (RT) and adjuvant TMZ in patients (pts) with newly diagnosed primary glioblastoma (ndGBM): Updated results from a phase Ib/II study 2023 ·Annals of Oncology ·María Vieito, Juan Manuel Sepúlveda-Sánchez, Víctor Moreno, Giuseppe Lombardi, Agostina Stradella, Rikke Hedegaard Dahlrot, Charlotte Aaquist Haslund, Marjolein Geurts, Estela Pineda, Petter Brandal, Filip De Vos, María Ángeles Vaz Salgado, Maria Martinez‐García, Marina Macchini, (unknown), Teresa Sánchez, Bishoy Hanna, (unknown), Zariana Nikolova, Matteo Simonelli	2
9	The benefit of complete resection of contrast enhancing tumor in glioblastoma patients: A population-based study 2023 ·Neuro-Oncology Practice ·(unknown), Erlend Skaga, Andrés Server, Henning Leske, Petter Brandal, Eirik Helseth, Pål Rønning, Einar Osland Vik-Mo	8
10	Incidence and outcome of pseudoprogression after radiation therapy in glioblastoma patients: A cohort study 2023 ·Neuro-Oncology Practice ·(unknown), (unknown), (unknown), Henriette Magelssen, Mette Sprauten, Tom Børge Johannesen, Einar Osland Vik-Mo, Henning Leske, Pitt Niehusmann, Karoline Skogen, Eirik Helseth, Kyrre E. Emblem, Petter Brandal	4
11	3D volume growth rate evaluation in the EORTC-BTG-1320 clinical trial for recurrent WHO grade 2 and 3 meningiomas. 2023 ·Journal of Clinical Oncology ·Émeline Tabouret, Julia Furtner, Thomas Graillon, Antonio Silvani, Émilie Le Rhun, Riccardo Soffietti, Giuseppe Lombardi, Juan Manuel Sepúlveda-Sánchez, Petter Brandal, Lucy Brazil, Martin Bendszus, Vassilis Golfinopoulos, Thierry Gorlia, Michael Weller, Felix Sahm, Wolfgang Wick, Matthias Preusser	1
12	P14.65 Survival in a consecutive series of 467 glioblastoma patients: impact of prognostic factors and recurrent treatment at two independent institutions 2021 ·Neuro-Oncology ·(unknown), (unknown), Mohummad Aminur Rahman, (unknown), Petter Brandal, (unknown), Martha Chekenya, Dorota Goplen	1
13	Normal tissue complication probability models in plan evaluation of children with brain tumors referred to proton therapy 2019 ·Acta Oncologica ·Camilla H. Stokkevåg, Daniel J. Indelicato, Klaus Herfarth, Henriette Magelssen, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Helge Egil Seime Pettersen, Marianne Brydøy, Petter Brandal, L.P. Muren	13
14	Paediatric radiation therapy across Europe: A European questionnaire survey supported by the SIOPe, ESTRO, PROS and several national paediatric hematology-oncology societies (NAPHOS) 2017 ·Annals of Oncology ·Charlotte Demoor‐Goldschmidt, C. Carrié, Gillian Whitfield, (unknown), Karin Dieckmann, Beate Timmermann, Lorna Zadravec Zaletel, Pavle Banović, (unknown), (unknown), (unknown), J. Giralt, (unknown), (unknown), (unknown), Patricia Daly, Petter Brandal, Geert O. Janssens, Umberto Ricardi, (unknown)	2
15	Genomic characterization of ependymomas reveals 6q loss as the most common aberration 2014 ·Oncology Reports ·Thale Kristin Olsen, Ludmila Gorunova, Torstein R. Meling, (unknown), David Scheie, Bernt Johan Due‐Tønnessen, Sverre Heim, Petter Brandal	9
16	Expansion of Multipotent Stem Cells from the Adult Human Brain 2013 ·PLoS ONE ·Wayne Murrell, (unknown), John Bianco, Biljana Stangeland, Mrinal Joel, Linda Paulson, Bernd Thiede, Zanina Grieg, (unknown), Håvard Kjesbu Skjellegrind, Ståle Nygård, Petter Brandal, Cecilie Sandberg, Einar Osland Vik-Mo, (unknown), Iver A. Langmoen	38
17	Sampling requirements in DCE‐MRI based analysis of high grade gliomas: Simulations and clinical results 2012 ·Journal of Magnetic Resonance Imaging ·(unknown), (unknown), (unknown), Raimo A. Salo, (unknown), Petter Brandal, Atle Bjørnerud	29
18	Genomic aberrations in diffuse low‐grade gliomas 2011 ·Genes Chromosomes and Cancer ·(unknown), Ludmila Gorunova, Petter Brandal, David Scheie, Eirik Helseth, Torstein R. Meling, Sverre Heim	10
19	Genomic aberrations in pediatric gliomas and embryonal tumors 2011 ·Genes Chromosomes and Cancer ·(unknown), Petter Brandal, Ludmila Gorunova, Eva Widing, Torstein R. Meling, Bård Kronen Krossnes, Sverre Heim	6
20	Similar cytogenetic findings in two synchronous secondary peripheral chondrosarcomas in a patient with multiple osteochondromas 2011 ·Cancer Genetics ·Anastasios Kyriazoglou, (unknown), Niki Arnogiannaki, Petter Brandal, Sverre Heim, Nikos Pandis	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact